Abstract: The disclosure provides a method for treating a subject afflicted with a tumor comprising administering to the subject a therapeutically effective amount of an anti-PD-1 antibody or antigen-binding portion thereof or an anti-PD-L1 antibody or anti-gen-binding portion thereof, wherein the subject is identified as having a high inflammatory gene signature score and a tumor that has a high tumor mutation burden (TMB) status. In some embodiments, the high inflammatory gene signature score is determined by measuring the expression of a panel of inflammatory genes in a tumor sample obtained from the subject, wherein the inflammatory gene panel comprises CD274 (PD-L1), CD8A, LAG3, and STAT1.

Abstract: The invention relates to the identification and cloning of a two novel full-length human SLAP-2 variants and their encoded polypeptides, hSLAP-2v3 and hSLAP-2v4. hSLAP-2v3 and hSLAP-2v4 are members of the SLAP family of adapter proteins and are involved in the negative regulation of intracellular T-cell signal transduction. The invention further relates to the use of these novel hSLAP-2v3 and hSLAP-2v4 polynucleotides and their encoded polypeptides as targets for therapeutic intervention in immunological and inflammatory disorders, autoimmune diseases, pulmonary diseases, proliferative immune disorders, and cancer.

Abstract: EGFR biomarkers useful in a method for identifying a mammal that will respond therapeutically to a method of treating cancer comprising administering an EGFR modulator, wherein the method comprises (a) exposing the mammal to the EGFR modulator and (b) measuring in the mammal the level of the at least one biomarker, wherein a difference in the level of the at least one biomarker measured in (b) compared to the level of the biomarker in a mammal that has not been exposed to the EGFR modulator indicates that the mammal will respond therapeutically to the method of treating cancer.

Abstract: The present invention relates to newly discovered human histone deacetylases (HDACs), also referred to as histone deacetylase-like polypeptides. The polynucleotide sequences and encoded polypeptides of the novel HDACs are encompassed by the invention, as well as vectors comprising these polynucleotides and host cells comprising these vectors. The invention also relates to antibodies that bind to the disclosed HDAC polypeptides, and methods employing these antibodies. Also related are methods of screening for modulators, such as inhibitors or antagonists, or agonists. The invention also relates to diagnostic and therapeutic applications which employ the disclosed HDAC polynucleotides, polypeptides, and antibodies, and HDAC modulators. Such applications can be used with diseases and disorders associated with abnormal cell growth or proliferation, cell differentiation, and cell survival, e.g., neoplastic cell growth, and especially breast and prostate cancers or tumors.

Abstract: A base station signal is applied to antenna elements. One signal from a first element is electrically modified and evaluated in conjunction with a second, unmodified signal from a second element. The modified signal is further modified and again evaluated with the unmodified signal. The results of the two evaluations are compared to determine a relative phase and/or amplitude at the respective elements.

Abstract: The present invention provides novel polynucleotides encoding human phosphatase polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel human phosphatase polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly cardiovascular diseases and/or disorders. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

Abstract: The present invention relates to newly discovered human histone deacetylases (HDACs), also referred to as histone deacetylase-like polypeptides. The polynucleotide sequences and encoded polypeptides of the novel HDACs are encompassed by the invention, as well as vectors comprising these polynucleotides and host cells comprising these vectors. The invention also relates to antibodies that bind to the disclosed HDAC polypeptides, and methods employing these antibodies. Also related are methods of screening for modulators, such as inhibitors or antagonists, or agonists. The invention also relates to diagnostic and therapeutic applications which employ the disclosed HDAC polynucleotides, polypeptides, and antibodies, and HDAC modulators. Such applications can be used with diseases and disorders associated with abnormal cell growth or proliferation, cell differentiation, and cell survival, e.g., neoplastic cell growth, and especially breast and prostate cancers or tumors.

Abstract: The present invention provides novel polynucleotides encoding human phosphatase polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel human phosphatase polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly cardiovascular diseases and/or disorders. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

Abstract: Several feed-forward RF power amplifiers configured for use in a distributed array, each having a main amplifier within a carrier null loop and an error amplifier within an error loop. Each carrier null loop includes a switch configured to selectively disable the carrier null loop, thereby disabling the carrier null loop, and injecting an actual RF signal into the error loop allowing the error loop to be optimized using the actual RF signal.

Abstract: Several feed-forward RF power amplifiers configured for use in a distributed array, each having a main amplifier within a carrier null loop and an error amplifier within an error loop. Each carrier null loop includes a switch configured to selectively disable the carrier null loop, thereby disabling the carrier null loop, and injecting an actual RF signal into the error loop allowing the error loop to be optimized using the actual RF signal.

Abstract: A zero-bias bypass apparatus for a low noise amplifier includes a bypass circuit, and a switching circuit coupled with a low noise amplifier and with the bypass circuit. The switching circuit includes one or more solid state devices responsive to absence of a control bias for switching an RF input signal from said amplifier to the bypass circuit with a low insertion loss and high isolation.

Abstract: A base station signal is applied to antenna elements. One signal from a first element is electrically modified and evaluated in conjunction with a second, unmodified signal from a second element. The modified signal is further modified and again evaluated with the unmodified signal. The results of the two evaluations are compared to determine a relative phase and/or amplitude at the respective elements.

Abstract: A system calibrates the gain of a repeater by determining a value based on the difference between respective amplitude measurements made while the repeater is transmitting and while it is not. The value is compared to threshold data in order to determine whether repeater attenuation should be incrementally adjusted.

Abstract: A zero bypass apparatus for a low noise amplifier includes a bypass circuit, and a switching circuit coupled with a low noise amplifier and with the bypass circuit. The switching circuit includes one or more solid state devices responsive to absence of a control bias for switching an RF input signal from said amplifier to the bypass circuit with a low insertion loss and high isolation.

Abstract: An antenna system for tower-top installation includes an antenna array of M×N antenna elements, a corporate feed for operatively interconnecting said antenna elements, a backhaul channel for communicating with ground-based equipment, and radio frequency circuits for processing radio frequency signals between the antenna array and a backhaul link. The radio frequency circuits include substantially all of the circuits required for the processing of radio frequency signals between the antenna array and the backhaul link.

Abstract: A zero-bias bypass apparatus for a low noise amplifier includes a bypass circuit, and a switching circuit coupled with a low noise amplifier and with the bypass circuit. The switching circuit includes one or more solid state devices responsive to absence of a control bias for switching an RF input signal from said amplifier to the bypass circuit with a low insertion loss and high isolation.

Abstract: A zero bypass apparatus for a low noise amplifier includes a bypass circuit, and a switching circuit coupled with a low noise amplifier and with the bypass circuit. The switching circuit includes one or more solid state devices responsive to absence of a control bias for switching an RF input signal from said amplifier to the bypass circuit with a low insertion loss and high isolation.

Abstract: A distributed antenna device includes a plurality of transmit antenna elements, a plurality of receive antenna elements and a plurality of amplifiers. One of the amplifiers is a power amplifier operatively coupled with each of the transmit antenna elements and mounted closely adjacent to the associated transmit antenna element, such that no appreciable power loss occurs between the power amplifier and the associated antenna element. At least one of the amplifiers is a low noise amplifier and is built into the distributed antenna device for receiving and amplifying signals from at least one of the receive antenna elements. Each power amplifier is a relatively low power, relatively low cost per watt linear amplifier chip.

Abstract: The present invention relates to newly discovered human histone deacetylases (HDACs), also referred to as histone deacetylase-like polypeptides. The polynucleotide sequences and encoded polypeptides of the novel HDACs are encompassed by the invention, as well as vectors comprising these polynucleotides and host cells comprising these vectors. The invention also relates to antibodies that bind to the disclosed HDAC polypeptides, and methods employing these antibodies. Also related are methods of screening for modulators, such as inhibitors or antagonists, or agonists. The invention also relates to diagnostic and therapeutic applications which employ the disclosed HDAC polynucleotides, polypeptides, and antibodies, and HDAC modulators. Such applications can be used with diseases and disorders associated with abnormal cell growth or proliferation, cell differentiation, and cell survival, e.g., neoplastic cell growth, and especially breast and prostate cancers or tumors.

Abstract: A distributed antenna device includes a plurality of transmit antenna elements, a plurality of receive antenna elements and a plurality of power amplifiers. One of the power amplifiers is operatively coupled with each of the transmit antenna elements and mounted closely adjacent to the associated transmit antenna element, such that no appreciable power loss occurs between the power amplifier and the associated antenna element. At least one of the power amplifiers is a low noise amplifier and is built into the distributed antenna device for receiving and amplifying signals from at least one of the receive antenna elements. Each said power amplifier is a relatively low power, relatively low cost per watt linear power amplifier chip.